science

Inotuzumab ozogamicin

Inotuzumab ozogamicin is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Inotuzumab ozogamicin rather than just read about it. In short: Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is administered by intravenous infusion.

Key takeaways

Inotuzumab ozogamicin belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Inotuzumab ozogamicin to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Inotuzumab ozogamicin from memory before moving on to harder problems.

Reference excerpt

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is administered by intravenous infusion. Inotuzumab ozogamicin consists of a humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin. The US Food and Drug Administration considers it to be a first-in-class medication.

Medical use Inotuzumab ozogamicin is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. In March 2024, the US Food and Drug Administration approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Adverse effects The US Food and Drug Administration label for the use of inotuzumab ozagamicin carries a boxed warning concerning the risk of liver toxicity, in particular hepatic veno-occlusive disease, which has been fatal in some people. The risk of this is higher in people who take the drug before having hematopoietic stem cell transplantation and more people die who have hematopoietic stem cell transplantation following treatment with this drug, than people who have hematopoietic stem cell transplantation, taking other chemotherapies. The risk gets higher as more rounds of treatment with inotuzumab ozogamicin are administered. The most common serious adverse reactions in people taking the drug in the clinical trial leading to approval include infections (23%), loss of neutrophils with fever (11%), hemorrhage (5%), stomach pain (3%), fever (3%), VOD (2%), and tiredness (2%). More than 20% of people had the following adverse reactions: loss of platelets (51%), loss of neutrophils (49%), infections (48%), anemia (36%), leukopenia (35%), tiredness (35%), hemorrhage (33%), fever (32%), nausea (31%), headache (28%), loss of neutrophils with fever (26%), elevated transaminases (26%), stomach pain (23%), and jaundice (21%). Between 10% and 20% of people also had loss of appetite, vomiting, diarrhea, mouth sores, constipation, chills, and injection site reactions. In studies in pregnant animals, the drug caused harm to the fetus at doses less than those used clinically, and so the drug has not been tested in pregnant women.

Pharmacology The antibody component of inotuzumab ozogamicin binds to CD22 receptors, which are expressed mostly on B cells. The whole conjugate is then drawn into the cell, where the ozogamicin is cleaved from the antibody by the acidic environment of the lysosome. The ozogamicin eventually travels to the nucleus where it breaks up DNA, causing the cell to die.

Chemistry Inotuzumab ozogamicin consists of the humanized monoclonal antibody inotuzumab (against CD22), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin. Ozogamicin is N-acetyl-gamma-calicheamicin dimethylhydrazide. It includes the same linker, called "AcBut", and toxin, as gemtuzumab ozogamicin, which arose from the same collaboration. The linker is a carbonyl-containing carboxylic acid. The antibody, originally called G5/44, was created by grafting the complementarity-determining regions and some framework residues from the murine anti-CD22 mAb m5/44, onto human acceptor frameworks.

History Inotuzumab ozogamicin was discovered by scientists collaborating at Celltech and Wyeth, and it was developed by Pfizer which had acquired Wyeth. Celltech and Wyeth entered into a collaboration in 1991 to develop antibody-drug conjugates. The humanized antibody portion was generated at Celltech and the DNA encoding it was transfected into CHO cells, which were sent to Wyeth, where chemists expressed and purified the antibodies and conjugated them with the linker to the cytotoxin; the work was published in 2004. Celltech was acquired by UCB in 2004 and Wyeth was acquired by Pfizer in 2009. In May 2013, a phase III trial in participants with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility. In March 2024, the FDA approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Efficacy was evaluated in a multicenter, single-arm, open-label study in 53 pediatric participants aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Two dose levels were evaluated--an initial dose of 1.4 mg/m2/cycle in 12 participants and 1.8 mg/m2/cycle in 41 participants. Premedications included methylprednisolone 1 mg/kg (maximum of 50 mg), an antipyretic, and an antihistamine. Participants received a median of 2 cycles of therapy (range: 1 to 4 cycles). The application was granted priority review and orphan drug designations.

Society and culture

Legal status In 2017, inotuzumab ozogamicin was approved by the European Commission and the US Food and Drug Administration for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia under the brand name Besponsa (Pfizer/Wyeth).

References

External links "Inotuzumab Ozogamicin". National Cancer Institute. September 2017. "Inotuzumab Ozogamicin". NCI Drug Dictionary. National Cancer Institute.

Illustrations

Worked examples

Example 1 — a first encounter with Inotuzumab ozogamicin

Start with the simplest possible case. Write down what Inotuzumab ozogamicin claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Inotuzumab ozogamicin before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Inotuzumab ozogamicin ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Inotuzumab ozogamicin

In research: Inotuzumab ozogamicin appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Inotuzumab ozogamicin in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Inotuzumab ozogamicin is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antibody–drug conjugate, Drugs developed by Pfizer, Drugs developed by Wyeth, so understanding it makes those chapters shorter.
In everyday life: Look for Inotuzumab ozogamicin outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Inotuzumab ozogamicin” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Inotuzumab ozogamicin in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Inotuzumab ozogamicin means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Inotuzumab ozogamicin out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Inotuzumab ozogamicin in simple terms?

Why does Inotuzumab ozogamicin matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Inotuzumab ozogamicin?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Inotuzumab ozogamicin.